Literature DB >> 1815046

Pharmacokinetics and bioavailability of diclofenac in the rat.

J E Peris-Ribera1, F Torres-Molina, M C Garcia-Carbonell, J C Aristorena, J M Pla-Delfina.   

Abstract

Diclofenac sodium is a widely used drug with interesting absorption and disposition features when administered to laboratory animals. The present study was undertaken to assess the pharmacokinetics of the drug after iv and gastrointestinal dosing to rats. Renal excretion of unchanged drug was negligible, but biliary excretion of the drug (unchanged and conjugated) was detected in bile duct-cannulated rats; it accounted for 27.2 and 31.2% of the total dose following iv and intraduodenal administration, respectively. Most of the drug excreted in the bile was conjugated diclofenac; unchanged drug accounted for only 4.7 and 5.4% of total diclofenac excreted in the bile after iv and intraduodenal dosing, respectively. In normal animals, intestinal absorption of the drug excreted in the bile resulted in higher drug concentrations in plasma than those obtained in bile duct-cannulated rats, but only after 60 min of dosing. When administered directly into the duodenum, diclofenac absorption was extremely fast and the maximum plasma diclofenac concentration was reached within 2 min. After oral dosing, an early peak was also observed, but it was lower than that obtained after intraduodenal dosing: 71% diclofenac bioavailability was found in bile duct-cannulated rats intraduodenally dosed, whereas in normal animals dosed by mouth a bioavailability of 79% was obtained. In normal animals intraduodenally dosed, an apparent bioavailability of 106% was observed. All of these features, particularly the influence of enterohepatic circulation on drug bioavailability, are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815046     DOI: 10.1007/BF01080872

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  17 in total

1.  Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren.

Authors:  W Riess; H Stierlin; P Degen; J W Faigle; A Gérardin; J Moppert; A Sallmann; K Schmid; A Schweizer; M Sulc; W Theobald; J Wagner
Journal:  Scand J Rheumatol Suppl       Date:  1978

2.  An equation for the systemic availability of drugs undergoing simultaneous enterohepatic cycling, first-pass metabolism, and intestinal elimination.

Authors:  T A Shepard; R H Reuning
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

3.  Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharm Sci       Date:  1985-02       Impact factor: 3.534

4.  Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation.

Authors:  J G Wagner
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

5.  A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow.

Authors:  K S Pang; J R Gillette
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

6.  Estimating the fraction reabsorbed in drugs undergoing enterohepatic circulation.

Authors:  F L Tse; F Ballard; J Skinn
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

7.  The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man.

Authors:  V A John
Journal:  Rheumatol Rehabil       Date:  1979

8.  Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites.

Authors:  H Stierlin; J W Faigle; A Sallmann; W Küng; W J Richter; H P Kriemler; K O Alt; T Winkler
Journal:  Xenobiotica       Date:  1979-10       Impact factor: 1.908

9.  Disposition and enterohepatic circulation of diclofenac in dogs.

Authors:  T Tsuchiya; M Terakawa; K Ishibashi; H Noguchi; R Kato
Journal:  Arzneimittelforschung       Date:  1980

10.  Studies on the reliability of a bihyperbolic functional absorption model. II. Phenylalkylamines.

Authors:  V G Casabó; E Núñez-Benito; A Martínez-Coscollá; E Miralles-Loyola; A Martín-Villodre; J M Plá-Delfina
Journal:  J Pharmacokinet Biopharm       Date:  1987-12
View more
  19 in total

1.  Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.

Authors:  D R H Huntjens; A Strougo; A Chain; A Metcalf; S Summerfield; D J M Spalding; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

2.  Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation.

Authors:  A J Stevens; S W Martin; B S Brennan; A McLachlan; L A Gifford; M Rowland; J B Houston
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

3.  Low bioavailability of amoxicillin in rats as a consequence of presystemic degradation in the intestine.

Authors:  J Chesa-Jiménez; J E Peris; F Torres-Molina; L Granero
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 4.  Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies.

Authors:  Urs A Boelsterli; Matthew R Redinbo; Kyle S Saitta
Journal:  Toxicol Sci       Date:  2012-10-22       Impact factor: 4.849

5.  Gastric mucosal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs in rats is mediated systemically.

Authors:  M V Skeljo; A S Giraud; N D Yeomans
Journal:  Dig Dis Sci       Date:  1993-11       Impact factor: 3.199

6.  Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity.

Authors:  Ze-Yu Zhong; Bin-Bin Sun; Nan Shu; Qiu-Shi Xie; Xian-Ge Tang; Zhao-Li Ling; Fan Wang; Kai-Jing Zhao; Ping Xu; Mian Zhang; Ying Li; Yang Chen; Li Liu; Lun-Zhu Xia; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

7.  A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.

Authors:  Toshiya Moriwaki; Hiroyuki Yasui; Akira Yamamoto
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

8.  Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac.

Authors:  K Tabata; K Yamaoka; T Fukuyama; T Nakagawa
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

9.  Effect of drug release rate on therapeutic outcomes: formulation dependence of gastrointestinal toxicity of diclofenac in the rat.

Authors:  Tahereh Khazaeinia; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2004       Impact factor: 4.473

10.  Microbial Glucuronidase Inhibition Reduces Severity of Diclofenac-Induced Anastomotic Leak in Rats.

Authors:  Simon T K Yauw; Melissa Arron; Roger M L M Lomme; Petra van den Broek; Rick Greupink; Aadra P Bhatt; Matthew R Redinbo; Harry van Goor
Journal:  Surg Infect (Larchmt)       Date:  2018-04-06       Impact factor: 2.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.